Search - tctmd.com

Displaying 881 - 900 of 1503

Sort: Relevancy | Date

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

More Liberal Definition of Type 2 MI May Misclassify Some Patients

News Daily News

More Liberal Definition of Type 2 MI May Misclassify Some Patients

September 20, 2017

Ischemic Heart Disease the Leading Cause of Death Globally

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Underweight and Overlooked: Low BMI Patients May Be Highest-Risk Post-PCI

News Conference News ESC 2017

Underweight and Overlooked: Low BMI Patients May Be Highest-Risk Post-PCI

August 26, 2017

CDC Says Only One in Three Post-MI Patients Get Outpatient Cardiac Rehab

News Daily News

CDC Says Only One in Three Post-MI Patients Get Outpatient Cardiac Rehab

August 25, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

News Daily News

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

August 15, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.